• Bioalliance SA, of Paris, was issued a U.S. patent for Oravig (miconazole for treating oropharyngeal candidiasis). That product already had two U.S. patents.

• Cell Signaling Technology Inc., of Danvers, Mass., was issued U.S. Patent No. 8,481,279, for methods to inhibit the progression of lung cancers, which express the EMLA-ALK fusion gene. The gene may have a connection to some non-small-cell lung cancers.

• Celldex Therapeutics Inc., of Needham, Mass., was issued U.S. Patent No. 8,481,029, "Human immune therapies using a CD27 agonist alone or in combination with other immune modulators." The patent covers its product candidate CDX-1127.

• Dipexium Pharmaceuticals LLC, of New York, received a U.S. Patent notice of allowance for Locilex (pexiganan acetate cream 1 percent), an antibiotic peptide in a topical cream, to treat skin or wound infections.

• Insite Vision Inc., of Alameda, Calif., received a U.S. Patent notice of allowance for Durasite 2, its next-generation system for delivering ocular drugs.

• Nupathe Inc., of Conshohocken, Pa., received a U.S. Patent notice of allowance for No. 13/105,585, "Transdermal Methods and Systems for the Delivery of Anti-Migraine Compounds." The application covers methods for migraine treatment using an iontophoretic patch containing a triptan that doesn't irritate patients' skin.

• Qrxpharma Ltd., of Sydney, Australia, was issued U.S. Patent No. 8,461,171, "Hybrid Opioid Compounds and Compositions." The patent is related to a hybrid morphine-oxycodone molecule where two different opioids are chemically linked.